United Therapeutics Corp

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis

    Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Do Analysts Recommend for United Therapeutics?

    23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”

    By Margaret Patrick
  • uploads///Part  Graph
    Company & Industry Overviews

    Alnylam Pharmaceuticals Initiates Phase 1 Trial of ALN-TTRsc02

    Alnylam Pharmaceuticals (ALNY) was one of the most underperforming biotech stocks for the week ended June 10, 2016. It fell 10% due to profit booking.

    By Peter Neil
  • uploads///pill _
    Company & Industry Overviews

    United Therapeutics: Recent Developments and Analysts’ Ratings

    On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).

    By Daniel Collins
  • uploads///FE
    Earnings Report

    How United Therapeutics Performed in 1Q18

    In 1Q18, United Therapeutics (UTHR) generated revenues of $389.2 million compared to $370.5 million in 1Q17.

    By Daniel Collins
  • uploads///Opsumit
    Company & Industry Overviews

    How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17

    In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in November 2017

    In November 2017, the U.S. Food and Drug Administration (or FDA) granted United Therapeutics’ (UTHR) Adcirca Pediatric exclusivity until May 21, 2018.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals

    On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Patisiran Expected to Become Key Growth Driver for Alnylam

    Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.

    By Margaret Patrick
  • uploads///Remodulin and Tyvaso
    Company & Industry Overviews

    How United Therapeutics’ Remodulin and Tyvaso Are Performing

    In 2Q17, United Therapeutics’ (UTHR) Remodulin generated revenues of around $158 million, which reflected ~8% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Technology Platforms and Research Programs Drive LGND’s Partnerships

    Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

    By Margaret Patrick
  • uploads///Orenitram Unituxin
    Company & Industry Overviews

    How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?

    In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals

    Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

    By Margaret Patrick
  • uploads///United therapeutics revenues
    Company & Industry Overviews

    How Did United Therapeutics Perform in 2Q17?

    In 2Q17, United Therapeutics (UTHR) generated revenues of around $445 million, which reflected ~8% growth on a year-over-year (or YoY) basis and ~20% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals’ Shots-on-Goal Business Model

    Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

    By Margaret Patrick
  • uploads///Analysts reco
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in August 2017

    In April 2017, United Therapeutics (UTHR) and 3D Systems (DDD) declared their plans to develop solid organ scaffolds for human transplants.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017

    Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Healthy Profit Margins in 2017

    Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ Expected to Report Robust Revenue Growth in 2017

    In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bioverativ–True North Therapeutics: Stronger Research Pipeline

    The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).

    By Margaret Patrick
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for United Therapeutics in June 2017

    Thirteen analysts covered United Therapeutics in June 2017. Two analysts recommended a “strong buy.”

    By Daniel Collins
  • uploads///United therapeutics revenues projections
    Company & Industry Overviews

    How United Therapeutics Is Expected to Perform in 2017

    In 2016, United Therapeutics (UTHR) reported ~$1.6 billion in revenues, reflecting ~9.0% YoY growth. In 1Q17, UTHR generated ~$370.0 million in revenues—an ~9.0% quarter-over-quarter decline.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue

    Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17

    To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    United Therapeutics: Will RemoSynch Become a Key Growth Driver?

    United Therapeutics (UTHR) has developed a targeted strategy for a successful launch of its investigational drug device combination, the RemoSynch implantable pump system.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why United Therapeutics Expects Strong Revenue Growth

    United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Valeant Pharmaceuticals Could See Modest Revenue Decline in 2016

    In 3Q16, Valeant Pharmaceuticals (VRX) revised its fiscal 2016 revenue guidance downward from $9.9 billion–$10.1 billion to ~$9.6 billion to ~$9.7 billion. In 2016, VRX suffered from talent retention issues, negative press coverage, and litigation.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Dupixent Is Being Explored for Multiple Indications in 2016

    In addition to being explored as a monotherapy for AD (atopic dermatitis), Regeneron and Sanofi are also researching Dupixent for other indications.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Physician and Payer Relationships to Increase UTHR’s Drug Access

    UTHR has been actively involved in strengthening its relationships with health insurers and physicians to ensure drug access for the patient community.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    $1 Billion Sales Target in Place for Tyvaso

    United Therapeutics’ Tyvaso’s strong profile and patent protection until the late 2020s is expected to enable it to reach annual sales of $1 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Generic Competition Not a Threat to UTHR’s Remodulin

    Though Remodulin is expected to face generic competition starting in 2018, UTHR is confident in maintaining the majority of its market share.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ALNY Should Complete Revusiran’s Endeavour Trial Enrollment in Late 2016

    If the Endeavour study results in positive data, Alnylam Pharmaceuticals may become a major rare disease player like its peers United Therapeutics (UTHR) and Vertex Pharmaceuticals.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ALNY Reports Positive Results from Patisiran’s Open Label Extension Study

    On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its ongoing Phase 2 open label extension study.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Understanding the Sales Potential of United Therapeutics’ Orenitram

    United Therapeutics’ (UTHR) Orenitram is an oral medication containing the prostacyclin analogue, trepostinil.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside United Therapeutics’ Growth Plans for Tyvaso

    United Therapeutics (UTHR) expects Tyvaso, a therapy administered through proprietary Tyvaso inhalation system, to witness strong growth in 2016.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    IBB Mid-Cap Outperforms XBI Mid-Cap

    IBB mid-cap outperformed XBI mid-cap for the week ended September 4, 2015. The IBB top ten mid-cap stocks returned -3.34%, while the XBI top ten mid-cap stocks returned -4.33% for the same period.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.